Frost & Sullivan

MARCH 22, 2024

However, the pharma/biopharma industry shows overall stagnant R&D activity. Small-to-mid and emerging biopharma players contribute over 16%. Growing demand for outsourcing, with contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) leading industry growth.

Ecosystems 52

Ecosystems Biopharma Biotech Contract research organization 52

Frost & Sullivan

MAY 3, 2023

4 th May 2023 – Frost & Sullivan studied the contract research organization industry and, based on its findings, recognizes George Clinical with the 2023 Asia-Pacific Competitive Strategy Leadership Award. SAN ANTONIO, TX. –

Contract research organization 52

Contract research organization Biopharmaceuticals Biopharma Business development 52

Frost & Sullivan

APRIL 25, 2023

April 25, 2023 – Frost & Sullivan researched the contract research organizations industry and, based on its analysis results, recognizes Emmes with the 2023 Global Competitive Strategy Leadership Award. years, to become a truly global company with a diverse mix of public sector and biopharma clients.

Biopharmaceuticals 52

Biopharmaceuticals Biopharma Biotechnology Contract research organization 52

Jake Jorgovan

FEBRUARY 1, 2024

CSSi LifeSciences CSSi LifeSciences is a global, innovative Contract Research Organization (CRO) and consulting group specializing in advancing therapeutics and medical devices through development and regulatory approval. The company provides customized solutions to mitigate risks, time, and expenses, supporting U.S.

Life science 130

Life science Biotech Biotechnology Engineering 130